DS-CDT claim coverage for counsel review.
This page is for patent and IP diligence, not the Data Buyer sales path. It explains claims 1-20 in plain language, separates implementation support from synthetic-demo and proxy support, and keeps exact source evidence in controlled review materials.
How to read this diligence map.
The statuses are counsel-facing review aids. They do not establish patentability, regulatory approval, clinical efficacy, production readiness, medical advice, or automatic partner data access.
Built as working product behavior or durable data structure.
Shown with synthetic data or a mock workflow. Useful for product review, not proof from real users.
A simplified stand-in shows the intended logic while real validation is still pending.
Needs pilot data, vendor access, signed terms, privacy review, legal review, or clinical review first.
Plain-English DS-CDT review map.
This counsel-facing map explains what each patent claim means, what the demo safely supports, and what still needs validation. Detailed implementation evidence belongs in controlled diligence materials, not on the public marketing path.
Dynamic Synthetic-Control Digital Twin: LifePrint's proposed evidence loop that compares a person's active protocol state with a modeled untreated baseline.
A comparison group or baseline created from matched data rather than a physical placebo group.
A safe approximation exists for review, but it is not yet validated with real pilot data or production partners.
Standardized Mean Difference: a balance check used to see whether two comparison groups look similar on baseline covariates.
Stabilized inverse probability of treatment weighting: a statistical weighting method used to reduce imbalance between treated and comparison data.
Personal identifiers are removed or transformed before data is used for partner review. Real production use still needs privacy review.
Data Use Agreement: a contract that defines who may access data, for what purpose, and under what privacy controls.
A demo score that flags meaningful movement across telemetry and lab context. It is not a clinical threshold.
System claims
Claims 1-8 describe the parts of the product system: inputs, blend decomposition, balancing, lab coverage, routing, and biological-age context.
The platform brings together protocol logs, wearable context, and lab results, then compares an active state with a modeled baseline.
The demo shows the full evidence loop with synthetic records, clear consent labels, and a reviewer-safe support status.
Real causal modeling and production partner use still need pilot validation and governance review.
Wearable measures such as HRV, resting heart rate, and sleep structure can add continuous context between lab events.
Synthetic wearable records illustrate how these signals can be aligned with protocols and labs.
Real device APIs vary by vendor, sampling frequency, and user permissions.
The system checks whether an active user and the comparison baseline look similar before interpreting differences.
The demo exposes balance status and explains the target in plain language.
Real-world balance depends on cohort size, covariate quality, and study design.
The evidence loop is designed around a broad lab panel across metabolic, endocrine, inflammatory, organ-function, and related markers.
The product data model and synthetic lab panels support broad biomarker coverage for review.
Clinical interpretation, reference copy, and any health guidance require medical review.
The product can decide when a follow-up lab panel would be worth requesting for evidence generation.
The website shows routing as mock/demo logic only and does not create real lab orders.
Real ordering requires vendor contracts, consent controls, legal review, and fulfillment safeguards.
Evidence records can be prioritized using a partner-demand model for protocols or cohorts.
The demo uses illustrative valuation categories to show how the decision could work.
Actual pricing needs signed commercial terms or measured market evidence.
The product can calculate a biomarker-derived biological-age style metric from lab context.
The UI frames biological age as research context and avoids treatment or diagnosis language.
Different biological-age methods need different inputs and separate validation.
The system can estimate how a biological-age style signal might move as telemetry and lab context change.
The demo presents this as a forecast proxy, not as a clinical prediction.
Forecast validity requires longitudinal evidence from real cohorts.
Method claims
Claims 9-15 describe the workflow: ingest data, decompose protocols, build the comparison baseline, score volatility, protect privacy, and prepare partner-facing evidence.
The product flow collects wearable context, protocol events, lab values, and blend information before building a comparison baseline.
Synthetic examples show each step of the workflow without using real personal health data.
Production ingestion still depends on provider access, consent, and data-quality controls.
Wearable context can be included when the system balances treated and comparison data.
The demo shows the concept through summary-level balancing diagnostics.
Raw production streams require separate data-quality and statistical validation.
The system can flag movement between wearable context and lab context that may deserve review.
The demo score is clearly labeled as a product signal, not a clinical threshold.
Thresholds require real-world validation before clinical or operational reliance.
The patent describes recommending protocol changes when signals cross a threshold.
The product intentionally stops at a review signal and does not provide medical dosing guidance.
This requires clinician ownership, legal review, safety review, and explicit product governance.
The system can represent high-frequency wearable context around health events.
Synthetic data demonstrates minute-level metadata for review.
Real wearable providers may expose different sampling and permissions.
Before partner use, personal records are transformed into a privacy-preserving evidence asset.
The demo shows privacy labels, consent framing, and a de-identification manifest shape.
Regulatory-grade use needs privacy audit, DUA scope, and governance approval.
A partner can request access to an evidence asset after consent, de-identification, and contract review.
The partner journey presents a request path without exposing raw data or making automatic access promises.
Commercial use requires signed terms, consent audit, de-identification review, and compliance review.
Software claims
Claims 16-20 describe the software instructions: compare active state to baseline, decompose blends, report balance, trigger mock routing, and model uncertainty.
The software compares protocol-era data with a modeled baseline and produces biological-age style context.
The demo shows the comparison and labels the outputs as synthetic or proxy-supported.
Production model monitoring and evaluation are still required.
A multi-ingredient protocol can be represented as separate molecular components for analysis.
The product demonstrates blend-to-component mapping without giving dosing advice.
The ontology needs ongoing domain review as products and protocol names change.
The software reports whether the modeled baseline is balanced enough for review.
The demo makes the balance target visible without claiming real-world validation.
Real SMD performance depends on actual cohort quality and study design.
The software can decide whether a lab panel should be requested when evidence value appears high enough.
The product labels this as mock routing and never creates a real order in the demo.
Real fulfillment requires vendor approval, legal review, consent controls, and operational QA.
The software can express uncertainty around a modeled baseline in a Bayesian-style way.
The demo uses a deterministic approximation to show the concept safely.
A trained Bayesian model requires real data, model validation, and monitoring.
Continue with the validation report.
Stay on this page to review what is implemented, synthetic-demo supported, proxy-supported, or blocked pending human diligence.
Validation report without public code exposure.
This counsel-facing summary explains what the DS-CDT demo can support, what is only synthetic or proxy-backed, and what remains blocked pending legal, privacy, clinical, vendor, or production review.
Implemented support
Working product surfaces and internal evidence demonstrate the shape of multimodal ingestion, compound decomposition, biomarker coverage, de-identification posture, and DS-CDT review outputs.
Synthetic demo support
The demonstration uses deterministic synthetic users, synthetic lab panels, synthetic telemetry, mock routing, and mock RWE assets. It does not use real PHI or create real lab orders.
Proxy support
Some statistical and model behaviors are safe product proxies. They show intended workflow and uncertainty handling, but they are not trained clinical models or production causal proof.
Blocked items
Clinical validation, vendor fulfillment, production de-identification audit, regulatory review, legal claim opinions, and commercial terms remain human-owned diligence steps.
Public pages stay plain-language.
LifePrint can explain claim meaning, status, limitations, synthetic-demo boundaries, and governance posture publicly. Exact source paths, test names, schema details, and implementation breadcrumbs should remain in internal documents, PR evidence, or controlled diligence rooms.